Brandon Li 0:00 Have our kind of editors, um, go in and and do their, uh, their work. Um, before we get started, did you have any questions for me? Any any feedback or or kind of context you needed?
Steve Brannan 0:11 No. I I think y'all did a pretty good job, and I got the little blurb on some of the things maybe we might wanna talk about. So
Brandon Li 0:18 Excellent. Um, you know, this will probably feel a little bit more like a meandering conversation. We've got, um, a few kind of points that we wanted to cover, but I tend to get curious and just kind of, um, go wherever, um, wherever you lead me.
Steve Brannan 0:31 Okay.
Brandon Li 0:32 Uh, and then, um, maybe one other piece of context. Uh, I am not a podcaster. This is not my day job. Um, I, uh, I happen to also be an entrepreneur. Um, I run a a company called Power. I'm not sure if you're familiar with our our kind of platform or our website.
Steve Brannan 0:49 Uh, I'm not familiar with your website.
Brandon Li 0:52 Uh, I mean, uh, in short, it's kind of like Zillow for clinical trials or Airbnb for clinical trials. I like to think of it as probably the best website on the Internet for individuals to learn about medical research. Yeah. Uh, the kinda net result of it is that we've had thousands of people sign up, um, over the last, um, last few years who are interested in neuroscience Yeah. And, uh, psychiatry research.
Steve Brannan 1:14 Well, I can see the need that you're you're expressing because it it we talk about all the time at our meetings. You know, like, how can you bring the science to, you know, the broader population so they can understand it? We won't dive too far into this, but you can see from some of the current political stuff, you know, people don't understand their really basic things like vaccines. Sure. Yeah. Um, so we we,
Brandon Li 1:38 you know, we wanna provide a an educational platform for individuals. And, um, uh, one of the interesting things has been, um, individuals who wanna go deeper and learn about some of the advancements in, um, in the research. Uh, hence we started this podcast, uh, to go speak with, uh, the leading experts in the world to tell us their stories. Um, the kind of byproduct of running a platform like this is that we also support a lot of patient recruitment activities. So, um, we work with a lot of sites and clinics and PIs who, um, also follow along the podcast and other sponsors that, um, are always curious to hear what's, uh, other guests have to say.
Steve Brannan 2:12 Well, if you think of it, it it's sort of curious, this cultural, uh, thing that happened where people are willing to volunteer to, you know, be a a subject in these things, and it's not gonna directly help them.
Brandon Li 2:26 Mhmm. ious to hear what's, uh, other guests have to say.
Steve Brannan 2:12 Well, if you think of it, it it's sort of curious, this cultural, uh, thing that happened where people are willing to volunteer to, you know, be a a subject in these things, and it's not gonna directly help them.
Brandon Li 2:26 Mhmm.
Steve Brannan 2:27 But but it's gonna help the community or mankind or something like that. That doesn't happen a lot in the world over the history of it. So we're living in a very interesting age where some of that is not widespread, but, uh, it's amazing that that has occurred and how much, uh, we've been able to learn because of things like that. So
Brandon Li 2:47 Yeah. Absolutely. It it's it's fascinating. We we ask everybody who signs
Steve Brannan 2:50 up for, like, with a profile on a platform,
Brandon Li 2:52 why are you doing this? Why are you, um, where you kind of why why are you here? Uh, and oftentimes, we'll hear some combination of, you know, as you would expect, my existing kind of regiment, uh, doesn't really work well for me. Um, so I'm kinda curious, uh, but then also, um, there's this, uh, other kind of, like, factor, which is, uh, I just I hope that I can kinda contribute to, um, helping others who are in a similar situation, uh, to me.
Steve Brannan 3:19 Well, think of the very recent COVID experience. You know, they ran these these things, and they did it so quickly. And I but how many people, you know, volunteer? And if you think about it, you're you're like, well, if it works, then that's great. But if it doesn't work and I'm on or even if it works and I'm on placebo
Brandon Li 3:37 Oh, boy.
Steve Brannan 3:37 Who had to anyway. Sorry.
Brandon Li 3:40 No. No. Not at all. Um, hey. May maybe this early conversation will, um, get snipped into a,
Steve Brannan 3:44 uh, a cold open or something. Okay. Um, well,
Brandon Li 3:47 what what what why don't we get going? Um, my first question to you, uh, will be just a, you know, career background. So it'll be a softball, and then we kinda go from there.
Steve Brannan 3:55 Sure.
Brandon Li 3:56 Well, Steve, thank you so much for taking the time to be on the show with me today.
Steve Brannan 4:00 Happy to be here.
Brandon Li 4:01 Yeah. Uh, for the audience, uh, Steve was the chief medical officer of, uh, Corona Therapeutics, uh, recently purchased by Bristol Myers Squibb, uh, having produced the first successful schizophrenia drug in, uh, in decades. So, um, really excited to be having this conversation and, uh, learning more from Steve about his, uh, his career to date. Please go ahead. e chief medical officer of, uh, Corona Therapeutics, uh, recently purchased by Bristol Myers Squibb, uh, having produced the first successful schizophrenia drug in, uh, in decades. So, um, really excited to be having this conversation and, uh, learning more from Steve about his, uh, his career to date. Please go ahead.
Steve Brannan 4:23 Yeah. Sure. Um, and it's not so much the first in decades, but it's the first new mechanism, um, medicine in decades. So kryptosine was out there a little while back and wasn't even a decade ago. But, um, uh, interestingly, you know, things sorta happen. Uh, there was another company working on something called a Tar One. We were working in the muscarinic space, and these are all different kinds of mechanisms. And, uh, things like depression, you have a lot of different medicines with different mechanisms of action, and some work better for some people than others. And so this was a real, uh, a posse of not of medicines, but of really different kinds of medicines. And so I think this is a big step forward in the schizophrenia field to have a different mechanism, and I think there'll be others that follow pretty quickly. So.
Brandon Li 5:12 Yeah. And I'm I'm excited to to kinda dive into, um, your view on the landscape, but maybe just, um, give us a a thumbnail sketch of your career and
Steve Brannan 5:19 and how you how you ended
Brandon Li 5:20 up working on, uh, on corona in the in the first place.
Steve Brannan 5:23 Sure. So, uh, my background, I'm trained, uh, as a psychiatrist, so medical doctor, then residency in psychiatry. And then I did a research fellowship, and it involved neuroimaging. That's been sort of foundational to my career. We had this radical idea that the brain was made of circuits. And, uh, of course, we all that's the normal thing that we we think about now. But so I've sort of said, you know, if you have something and it it involves a circuit in the brain, I have half a chance of understanding it. Anyway, but I was in academic medicine for a while, did neuroimaging research, uh, mainly with mood and anxiety disorders. And then, um, Eli Lilly came and I say made me an offer I couldn't refuse, so I went and worked on an antidepressant, uh, duloxetine or Cymbalta there. And Then I've been with several companies, uh, since then, both large and small. Been fortunate enough to be involved in a number of different things that actually got approved and on the market. Uh, and then the last one really had to do with, uh, KRUNA Therapeutics. So I I joined 2017. They were sort of reviving it and had this great new idea. And so I was employee number two, and so I saw the whole thing really from almost the start to to the end. Um, so that was sort of exciting. You don't you usually only get to see a part of the story, not the the major part of it. So and we were very fortunate to not really and we never skipped a beat. We never really had a stumble, so things went very quickly. Um, and then recently, of course, uh, it was approved and is out on the market as of, you know, last fall. So ou usually only get to see a part of the story, not the the major part of it. So and we were very fortunate to not really and we never skipped a beat. We never really had a stumble, so things went very quickly. Um, and then recently, of course, uh, it was approved and is out on the market as of, you know, last fall. So
Brandon Li 7:01 Yeah. Congratulations on the, uh, on the incredible, uh, on the incredible milestone there, Steve.
Steve Brannan 7:07 Thanks.
Brandon Li 7:08 And and kind of prepped for this conversation, I was reflecting back on a on an episode I did with, uh, doctor Anantha, uh, Shankar over at UPMC. Um, and he mentioned that the the compound was essentially going to be dropped by Lilly as an Alzheimer's drug before you you spun it up. Uh, I'd love to get the kinda inside story as to, like, how you identified this as a thing that's that needed spinning out in the first place. ctor Anantha, uh, Shankar over at UPMC. Um, and he mentioned that the the compound was essentially going to be dropped by Lilly as an Alzheimer's drug before you you spun it up. Uh, I'd love to get the kinda inside story as to, like, how you identified this as a thing that's that needed spinning out in the first place.
Steve Brannan 7:28 Well, and others were more involved in that than I was, but but, uh, Anantha and then, uh, Alan Breyer and even Steve Paul, uh, who'll come back into the picture later, uh, at Lilly had done this, and and it it was interesting. This molecule looked like it was they were using it for Alzheimer's, and then they they sort of serendipitously found that it was really good for what they were calling behavioral problems associated with Alzheimer's, but it's really psychosis psychotic symptoms. And it looked for all the world like if this drug was really good at that, um, but it also had a number of side effects, and they weren't able to kind of figure out how to make it more tolerable. And so, uh, it did sit on this shelf for a long, long time. And then, uh, in, I guess, 2010 to 2017, sometime in that area, they they sort of looked at this, talked to some people, and they said, you know, this was really good. Uh, oh, and Anantha had done this study in schizophrenia patients, real small, ten and ten, but it showed this huge effect. So there were people out there saying, if you can just harness this, this would be a great drug. And, uh, what, uh, Andrew Miller and Eric Linko and some of these other people did, they were at what we call an incubator. You know? So in in Boston, there's this incubators like Third Rock or PureTech, and they have a number of different companies. And so they they sort of help them all grow. And then if one of them makes it, they can do another ten and two of them make it there. They all do really well. So, um, yeah, we were one of the ones that did really well. So, um, they, uh, and and the industry had sort of been looking at this muscarinic, uh, issue. And a number of the companies I had been working on, we we were all looking at it, but the wrong way and sort of what we're trying to make it more sensitive to one type of receptor than another, which is a not uncommon thing that people do. But what did is they sort of said, well, that's most of the benefits are central in your central nervous system Mhmm. And most of the side effects are peripheral. Now your central nervous system is protected, so not all things can get in there. So what if we block the peripheral side effects with an anticholinergic? The muscarinic is procholinergic. And, uh, but the if the anticholinergic can't get into the central nervous system, then we'll preserve the benefits and mitigate the side effects. And that essentially is exactly what happened. So when I sort of heard about this, uh, when they were, uh, talking to me, I was like, wow. You know, why didn't I think of that? You know? That's so simple that, you know, it's this gestalt like thing. You know? And and once it's out there, then people are like, oh, okay. Yeah. That makes sense and so on and so forth. So, um, anyway. I'm I I'd love to kind of dive into that h, talking to me, I was like, wow. You know, why didn't I think of that? You know? That's so simple that, you know, it's this gestalt like thing. You know? And and once it's out there, then people are like, oh, okay. Yeah. That makes sense and so on and so forth. So, um, anyway. I'm I I'd love to kind of dive into that
Brandon Li 10:26 a little bit more. Like, um, you were moving at the time from Eli Lilly to, uh, to go join, uh, Corona. Is that right? No. Oh, okay.
Steve Brannan 10:37 I went a long career from, uh, Eli Lilly to Cyberonics to, uh, Novartis to Takeda. I had been at Forum, which was a company looking at cognition and schizophrenia. And, um, so, uh, they had, unfortunately, not done well in their phase three, and so the company dissolved. And so I was available to then, uh, be recruited at, uh, Corinna. Yeah. And Yeah. Go ahead.
Brandon Li 11:07 Well, I was gonna say and having seen, um, it sounds like, um, the largest of, uh, large pharma, the biotech adventure, how did you think about making the switches back and forth? I don't think I've spoken to a lot of folks who've, um, gone from one and the other and then and then back and forth in the same way that you have.
Steve Brannan 11:23 Yeah. I, um, this may sound a bit arrogant, so I apologize. But not everybody can do well at both small and large. And, uh, there's some you know, you get into and and there's pluses and minuses to to both. Uh, at Takeda, uh, before I went to forum, uh, I was I was the head of LinkedIn with a very large company. And you had a lot of resources, and you could do a lot of things.
Brandon Li 11:50 Um, but
Steve Brannan 11:50 you also have a lot of layers and a lot of people who are wanting to contribute to your, you know, your studies. And, uh, it's not always useful, particularly in CNS. Um, so the smaller companies are a little more, um, agile and innovative. They can take risks that the big companies don't. Like most big entities or bureaucracies, big companies tend to, uh, not be the risk takers. And so, um, this development program is very risky, you know. So this was a new mechanism. Um, people who fund this stuff like, oh, is this the same mechanism? Because then I can fund it. If it's a new mechanism, I'm not so sure. So that's always a barrier. Um, and and then, um, this whole idea of, uh, the combining the antagonist with the agonist was, you know, different and new, and so that that boggles a lot of people. And then once we were able to get on track, uh, and get going, we were able to move quicker than many of the larger companies do, but we won't go into that. That'll be another, uh, discussion sometime down the line.
Brandon Li 12:56 Oh, I was gonna I was gonna follow-up and ask about that, but but Okay. Yeah. Please. Yeah. I I mean, I was gonna say that, you know, as you kinda mentioned, uh, you you almost experienced this, like, charmed path, uh, along the way. Like, what do what do you attribute that to? me down the line. Oh, I was gonna I was gonna follow-up and ask about that, but but Okay. Yeah. Please. Yeah. I I mean, I was gonna say that, you know, as you kinda mentioned, uh, you you almost experienced this, like, charmed path, uh, along the way. Like, what do what do you attribute that to?
Steve Brannan 13:12 Um, it was sort of the right time and and the right people. Uh, so when I joined, uh, Sharon Sawchuk, who's our clean ops person, what what came right with me, uh, although she didn't join the company, she was more of a a consultant for a while. Um, but we had a lot of experience. She'd been at, uh, GSK for a long time. I had this career path and had been at very high levels of stuff. So I strategically knew the the whole pathway from early to late. Uh, and then I knew a lot of the CROs and stuff like that, so I could just and sites. Uh, all a lot of the sites that were available knew who I was. I I sort of tweaked, uh, some of the early Karuna people by saying, yeah, the the the sites that are working for us, they're not doing it because they know Karuna. That means nothing to them. They're doing it because they know me, and they know Sharon. Mhmm. Um, so we we knew the right sites. We know some of the CROs, uh, and talking to some of the CROs. And just like myself, one of the reasons I I went to CROON is I was looking at this. I'm like, wow. That science is really cool. That's that's great. And if it works, it's gonna be wonderful. And everybody likes this. So when we were going out there and I would tell people, they're like, wow. That's really cool. And so we got a lot of help from some of these vendors like Syneos and Cygnet that maybe not all small companies get. Uh, partly Mhmm. As they knew who I was in in my track record as well as Sharon. So we were both very well known entities with good records. And, you know, we were working on something really cool, so that that combination really got us a lot of high quality resource and and attention that small companies don't always get in life.
Brandon Li 14:55 Yeah. Yeah. How much of this is, uh, your ability to, um, take the science and tell incredibly, like, inspiring story. we were working on something really cool, so that that combination really got us a lot of high quality resource and and attention that small companies don't always get in life. Yeah. Yeah. How much of this is, uh, your ability to, um, take the science and tell incredibly, like, inspiring story.
Steve Brannan 15:05 That that is really key, uh, and this goes way back to when I was in neuroimaging. I worked with somebody named Helen Mayburg who's now really well known, but she was just starting out. And when you do the neuroimaging, it it's like you have all these blobs, you know, and Yeah. Color them, so they they call it blobology somewhat. But but, you know, you're looking at this, and what does this mean? And where she was really great is she said, no. No. No. Here yeah. This is the big delay. Remember, it connects here, here, and here. You know? It connects to Yeah. Campus. You can see it here. And being able to concisely, uh, and clearly delineate a story out of the, you know, the somewhat chaotic massive stuff that's going on is is really a key. And I think that did help. And when Steve Paul joined us a little bit later, he was really a masterful storyteller and and could really especially with the, um, the money people. You know? He he's like, look. Here's why you need to invest and so on and so forth, and and he was really great at that. So we we had a con we had some really good people. And as we grew, I think we also, hired, um, above average folks, you know, going along with us for the most part, not not all the time. So that that also helped. Um, the other thing I talk about in, um, that's been happening, like, maybe twenty years ago, the CNS trials really were hitting the skids. Mhmm. Not much was working. There's still problems there. Uh, there there's all sorts of problems we can talk about a little bit, you know, having to do with placebo and precision of diagnosis and all these sorts of things. And, uh, one of the things I talked about a lot in this clinical trial methodology is you learn from your mistakes and from other people's mistakes. Mhmm. And I've been round enough. You can see my gray hair. You know? Lots of mistakes. Lot of my own, so I've got another people. Sure. And with Kruna, we just didn't make the same mistakes. So we we knew what to avoid. We knew the pitfalls and really avoided pretty much everything.
Brandon Li 17:07 So Say say more about that. What what what were the mistakes that you intentionally designed around? ot of my own, so I've got another people. Sure. And with Kruna, we just didn't make the same mistakes. So we we knew what to avoid. We knew the pitfalls and really avoided pretty much everything. So Say say more about that. What what what were the mistakes that you intentionally designed around?
Steve Brannan 17:12 Um, well, uh, one thing, uh, I'll kinda put these in phrases, but, you know, more is better. No. It's not. Um, when you're doing these trials, you're trying to see a signal. And and there's some difficulties with, especially psychiatry, but CNS in particular, that a lot of our endpoints are soft. So unlike a hemoglobin a one c or doing a, uh, neuroimage of a tumor and see if it's grown, you don't have that. You know? So our depression, are you feeling less depressed today? Yes or no? Or less anxious? You know? It it's not a very hard, solid thing, and and, by the way, it fluctuates during the day. So, um, you have to deal with things with what I call a lot of variance. So you're looking for a signal, and you want a large signal. And, fortunately, the, you know, the COBINFI, the CAR XT that we have had a big signal, but you're also trying to diminish the variance, the inherent variance that that is occurring in these trials. And so there's a number of things that you can do. Now there's probably a limited number of really high quality sites doing this kind of work in The US. And so the the problem with doing too much is, like, you you go past I don't wanna say they're bad sites, but you you go past the a sites into the b sites and then the c sites and then the d sites. And so you just add more variance, and it makes it more difficult. Uh-huh. Um, the other thing is to go at the right pace. Now I have nothing against going fast. I like going fast. But when I have a car in front of a brick wall, I don't accelerate. It it's just Sure. Uh, I used to ask people, uh, in talking to folks is how many times you've been asked, uh, to make a trial go faster, and everybody holds up their hands. I ask, uh, how many have you been asked to slow down a trial? Nobody holds up their hands. And so the this huge imbalance, you know, just tells you something, and people sort of can't help themselves. When I was at Takeda, we had we're looking at an antidepressant, and we had the first wave of studies in The US, which was zero for eight. Uh, the second set of the second wave of studies was four for five positive. So zero for eight, four for five, same compound. Well, one of the things was, you know, not getting in a hurry and doing stupid stuff. And, um, when we were making that transition, I remember talking to our staff, both Lundbeck and and Takeda, because we were doing it together, and said, okay. I'll I'll guarantee you one thing about this second wave of studies. They will not be as fast as the first time. Does everybody understand? Yes. Yes. We understand. Thanks. Uh, great. So that means you're not gonna come and say anything. No. No. We're not gonna do that. Like, great. I'm from Texas. You just saw my thumb. Get out a knife, cut your finger, and sign in blood. No. No. No. We're not gonna do that. Pause. How long it was until that somebody asked me a little faster? nd. Thanks. Uh, great. So that means you're not gonna come and say anything. No. No. We're not gonna do that. Like, great. I'm from Texas. You just saw my thumb. Get out a knife, cut your finger, and sign in blood. No. No. No. We're not gonna do that. Pause. How long it was until that somebody asked me a little faster?
Brandon Li 20:04 But let's go let's go one month.
Steve Brannan 20:07 Oh, it was actually only it was six months.
Brandon Li 20:09 Six months. Okay. Alright.
Steve Brannan 20:11 But but, yeah, they and that, you know, it it was both Lundbeck and Takeda, their upper management, not talking to each other. But within a within a week of each other, they they were asking. So it's just inherent. They they can't help themselves. And and you need somebody and, you know, that has the courage to sort of say, you know, no. We're not we're not doing that. Here's the reasons. You you just can't say no. But what remember why. Go ahead.
Brandon Li 20:39 What is the actually, your honor roll, um, I'll ask the follow-up question afterwards. Uh, we we had diminished variants. We had right pace. Was there was there anything else that, um, was critical here? doing that. Here's the reasons. You you just can't say no. But what remember why. Go ahead. What is the actually, your honor roll, um, I'll ask the follow-up question afterwards. Uh, we we had diminished variants. We had right pace. Was there was there anything else that, um, was critical here?
Steve Brannan 20:52 Yeah. You you need a collaborative stance with your sites. Uh, the sponsors run these trials. Uh, you have these big seros that are helping you kinda do this. And then there's the site networks all across the globe. Uh, in this case, we were just working with US. And having had experience with them and they had experience with me and with Sharon, which was the team is really keen on working with these sites. And so, um, you have to be able to work together sorta hand in glove. And so you're you're never completely on the same page. So, uh, but you have to go to them and say, you know, I need the right patients at the right sites. Sounds simple, but but it's a lot harder, and I think you're one of the right sites. We're gonna work with you. We're gonna watch everything, but, you know, I wanna work with you and give you what you need to get these the right subjects. And, you know, that we have inclusion and exclusion exclusion criteria. Excuse me. Um, and, uh, but that alone doesn't quite get it. And a lot of these people, the PIs in particular, will have this sort of sixth sense. You know? Somebody comes in, they're like, they're not quite right. I can't figure it out. Uh, and what I want them to feel is I don't jump in their face, but I want them to feel my hand on their shoulder at that moment and say, oh, I wonder if doctor Brandon would really want this patient in the study. And, uh, again, you have to work with them. We had somebody in one of our, uh, studies. We had a the pans from eighty to one twenty. So 80 was the cutoff, and anybody scoring an 80 on the PANSS probably needs to be hospitalized. Um, so one twenty is really way out there, and they brought in somebody at a one eighteen or one nineteen, uh, at screening. And then there's a time before they get to baseline. And and I remember talking to him. I said, I don't think you're gonna make it because this person's already, you know, really psychotic, and you're you're can't do the study as well. You you just treat him. And they're like, no. No. I think I can do it. And I was like, okay. You know? But, you know, if they're above blah blah blah at the baseline, then, you know, I'll I'll try not to say I told you so, but, you know and, of course, that's what happened. And so they came back, and they were like, you know, I I thank you for letting me try. I don't know what I was thinking, but I promise you I will get you with the right patients as we're going forward. And at that moment, I knew, you know, that site was gonna do well for us, which they did. So in hindsight
Brandon Li 23:22 go ahead. Yeah. Um,
Steve Brannan 23:25 in this dynamic where, you know, there's a handful of hinking, but I promise you I will get you with the right patients as we're going forward. And at that moment, I knew, you know, that site was gonna do well for us, which they did. So in hindsight
Brandon Li 23:22 go ahead. Yeah. Um,
Steve Brannan 23:25 in this dynamic where, you know, there's a handful of
Brandon Li 23:28 sites that you know are incredibly high quality that you wanna work with, how do you think about competition, um, at this site? Um, you know? Yeah. Um, you aren't the only one working on it. Yeah. Well
Steve Brannan 23:38 and and when we first started, by the way, there was only one other company running in patient schizophrenia trials, and that over only overlapped by a few months. So so that was also a time that helped us. There's no doubt that that when there's less competition, you're you're gonna and now after we've succeeded, now there's a bunch of people competing for these subjects. So there'll be inherently more variance, and the quality will suffer a little bit. Um, I I think one of the things, uh, and, again, I don't know why people don't do this because I don't think it's rocket science, but apparently, it is. It's like when when we we put together a protocol, and I'm like, okay. This is something what I'm gonna do. So I'll send it to the CRO. I'll send it to a couple of sites. And it's not that I think any one site knows more than I do about a trial, particularly a specific trial, but no one person knows everything and sees everything. So every time I've done this, somebody has come back with not just one, but usually, you know, a handful of things, if not more, like, oh, this would more make more sense if you did this or this. And for the sites like you, you you're they they're looking at, you know, if I bring in a patient on this day, you know, if you've got five different things, I can do this. But but if you got 10, you know, how is this all gonna fit together in in in a reasonable way? So they can be very, very helpful in those sorts of things. So, uh, and just the fact you know, since people don't do this, so we do. We we we ask for feedback. Uh, we don't take all the feedback, but we listen to everything. And I think they know that, so that's part of it. And, um, and then we're some of the sponsors and some of these are small biotechs. They they're small. They don't have enough people. They don't know better. Uh, they might just leave it to the CRO to to run the sites. We don't do that. Like, talk to me anytime day or night. So Yeah. And and I wouldn't especially toward the end, I wasn't the person that he would necessarily call first, but, uh, having that availability. And then, uh, there are certain meetings throughout the year that being a small company, we couldn't go out and visit people. Uh, we didn't have the money or the time, and, uh, but we could these meetings where people go to, like, CNS Summit or stuff like that or ASCP, we always said, we're here at the meeting. We wanna talk to you. And so we would spend time talking to the sites with site networks extensively. And I would bring my ClinOps team. So didn't have the money or the time, and, uh, but we could these meetings where people go to, like, CNS Summit or stuff like that or ASCP, we always said, we're here at the meeting. We wanna talk to you. And so we would spend time talking to the sites with site networks extensively. And I would bring my ClinOps team. So
Brandon Li 26:04 Certainly. I I I think that a common thread that I've seen in some of the smoothest programs that I've witnessed has been a, uh, a direct relationship between the sponsor team and the site team, uh, to build that trust, to build that collaborative, um, experience, uh, where you really do listen to feedback and iterate on the basis of it.
Steve Brannan 26:22 So I don't know if you will use this in your podcast or cut out. I'll just tell you one quick story.
Brandon Li 26:27 Yeah. Yeah. You tell me if you wanna cut it out, and we could cut it out. ve, um, experience, uh, where you really do listen to feedback and iterate on the basis of it.
Steve Brannan 26:22 So I don't know if you will use this in your podcast or cut out. I'll just tell you one quick story.
Brandon Li 26:27 Yeah. Yeah. You tell me if you wanna cut it out, and we could cut it out.
Steve Brannan 26:29 Well, you know, my altitude. So you got so, uh, BMS came with us to the ASCP meeting. It was sort of right after the transition had occurred in mid March, and this is sort of in in the May. And, uh, so we were at with one of these site groups and, uh, at the you know, I'd said something about, you know, don't talk to me, talk to these people because I'm just a consultant now. So dessert they brought out was, you know, black candles and stuff like that. Like, so so it's for my demise or whatnot. They all sang a song and whatnot. And so I'm walking back with the DMS people, and they're looking at me, and they're like, they really like you. I'm like, yeah. It's like, I never thought about that. I'm like, well, it's important. They're like, why is it important? I'm like, because there's three other trials out there, you know, competing for the same time and space. And they I don't think people well, I'm sure my competitors might disagree. I don't think people gave us more than they should have, but they certainly gave us a fair shot in the in the grouping of stuff. And and then you also have to watch things. So I've we have something called blinded data analytics, and so there was a site that, uh, had three people over the age of 55. The median age in the trial is, like, 42 to 44, something like that. So it's certainly possible, but it's highly unlikely. Not not three. One, if you don't even pay attention. Two, you sort of look at it. And then when by the time the third is like, uh, so, um, so I called up the site, but you don't jump down the throat. I just called the guy, the PI, and I said, hey. How long is the geriatric convention in town? What are you talking about? I'm like, well, I I saw your first three patients were all over the age of 55, so I couldn't figure out why that would happen. And then I thought, oh, there's a geriatric convention in town. How long is it in town? It was like, okay. I'll I'll get back to you. And and, you know, he never answered the question, but the next three patients they did were all under the age of 55. So, um, and I know what he was doing is there was another trial, uh, from one of our competitors that had a endpoint of 55. And so Oh. Giving us the ones over that age, and then all the others were going into the other trial. And I I was sort of subtly reminding him that I didn't particularly like that. So Right. Savvy. Savvy. Well, that's the advantage of years. Right? Experience. Well, I I think that that kind of gentle touch is important
Brandon Li 28:59 to kind of, uh, reflect on because, e others were going into the other trial. And I I was sort of subtly reminding him that I didn't particularly like that. So Right. Savvy. Savvy. Well, that's the advantage of years. Right? Experience. Well, I I think that that kind of gentle touch is important to kind of, uh, reflect on because,
Steve Brannan 29:02 um, it's a way to kind of stay aligned without antagonizing. You got it. That that's exactly right. You you you can't be a mean bastard son of a bitch. Right? You people don't like working with you that way. Uh, but you you can get your points across. I use humor a lot, uh, to to do some of that, and that seems to work for me. But
Brandon Li 29:24 Yeah. Certainly. Do do you think that
Steve Brannan 29:28 this, you know, this, like, uh, this gentle touch is a thing that's easy to propagate at a at a BMS? Uh, I don't think it's easy to propagate anywhere. Fair enough. And, um, I think, um, Yeah. I've even had some people, uh, talk to me. It's like, can you, you know, write a book or do a videotape or a podcast or something? You know?
Brandon Li 29:52 Right. This this will be it. This will be the canonical podcast.
Steve Brannan 29:55 That okay. So you'll be the star.
Brandon Li 29:57 The the well, you'll be the star on the on the interweb.
Steve Brannan 30:00 Oh, I I sorry. I meant start.
Brandon Li 30:02 Oh, the start.
Steve Brannan 30:03 Of course. The beginning. Yeah. And some of this, you know, has to do are you still there? Yeah.
Brandon Li 30:14 Oh, strange.
Steve Brannan 30:15 Yes. Yeah. Yeah. Okay. Um, I I sort of fold this into something else, character. Uh, so, um, you're off the screen again. Not sure if that means something's not working. Hello? Hello? I can't hear you.
Brandon Li 31:04 I'm back.
Steve Brannan 31:05 Uh, okay. Yeah.
Brandon Li 31:07 Alright. So let me just make sure we're still recording. I think we are still recording. I think the last track got uploaded. Alright. Um, we'll continue. But let's let's go back to, um, scaling this across, uh, across larger organizations. : I'm back.
Steve Brannan 31:05 Uh, okay. Yeah.
Brandon Li 31:07 Alright. So let me just make sure we're still recording. I think we are still recording. I think the last track got uploaded. Alright. Um, we'll continue. But let's let's go back to, um, scaling this across, uh, across larger organizations.
Steve Brannan 31:20 Yeah. It it it's and it gets a little bit to a person's character, you know, which is a a real important kinda thing. And and in the big companies in particular, you can get people who just make a living saying no. Mhmm. And, uh, when when I hire people, I look at at this, and it's like, what are they really in this for? Are they just in for themselves, or are they, you know, are they doing it for the good of mankind? You know, there's usually, uh, as a psychiatrist, there's mixed motivations. There's always mixed motivations. Sure. I do look in that mixture, I I look for something other than just themselves. And and, uh, oftentimes, when you have that, for the most part, you know, there can be particularly for, uh, clinicians, people can be pretty direct. And I had to learn over the years to be a little less direct and a little more diplomatic. Um, but, um, I I think people's desire to sort of collaborate and and work as a group is an important thing in these sorts of things. So if you can get that and sort of accentuate the teaching in that direction, that's probably how you need to go.
Brandon Li 32:26 Certainly. Hey. I would love to just backtrack very quickly to, um, a discussion we were having around the right pace. Yeah. What how do you know when you're on the right pace, uh, when you're going too fast or if, uh, you know, you're you're actually taking the time you need?
Steve Brannan 32:47 Yeah. So there's a couple things. One one is, and you know, we would do as a small company, we didn't have the internal capacity, but we would be talking to several of what we call CROs or contract research organizations. And so we'd say and then with experience, like, Sharon would know this off the, you know, back of her hand, but, you know, what what is typical for a site to do? And so it's a half a patient per month, uh, and then so that's Mhmm. Six per year, blah blah blah. And so you you calculate your time lines. And then I've learned because people get too literal about this and say, oh, the time line's gonna be twelve to eighteen months Yeah. Or fifteen months plus or minus three. And and so they seem to be able to handle that a little bit better. Because if I tell them it's gonna be fifteen months, then they're they're just at fifteen months, they're gonna be like, oh.
Brandon Li 33:41 What's going on? Yeah. Yeah. Yeah. Yeah. Are we behind it? Yeah. Or fifteen months plus or minus three. And and so they seem to be able to handle that a little bit better. Because if I tell them it's gonna be fifteen months, then they're they're just at fifteen months, they're gonna be like, oh. What's going on? Yeah. Yeah. Yeah. Yeah. Are we behind it?
Steve Brannan 33:45 And, um, so you you know and, again, this is a range, and you can look historically at ranges, particularly CROs can with particular sites. Um, and then you look, uh, very closely early on, um, and this was in the second wave of studies we did at, uh, Takeda with Lundbeck. And Lundbeck, quite frankly, I think, was the ones who who did this. When sites first come in, you you let them kinda go, but you watch very closely. So you watch the, um, quality of the data. You look for what we call deviations or very, um, from the the typical thing they're supposed to do. Uh, you look for any signs of quality problems. Yeah. You might look at, uh, of the patients that come in, I told you there was this 80 to one twenty. Usually, you don't have to worry about high end, but if they're supposed to be at least 80, you don't want a bunch of patients, you know, eighty, eighty one, 82, 85. You you wanna see see a spread because that's the normal way things happen. So in our trial, the mean was, like, 97, and for most of the sites, you you saw this, uh, normal distribution. Right. So, uh, and and so you you're looking for things like that to make sure things are not amiss or there's no red flags or discrepancies in what you're doing. So and then there's some things now they do with raters. So a lot of this, we we have to do. Again, these are soft measures, outcome measures. And so, like, the PANSS is this, uh, questionnaire you you basically have, and and that you you need trained raters. Mhmm. And then you have backups to the raters. You have uh, the site raters, which are the better raters in the most part. But you have central raters to sort of back up, and and they're rating the same audio tape or video audio tape. Mhmm. Um, and, you know, if the site rater has something, you know, a couple points lower and the the central rater has a couple points higher, it's like then then you look at all these things, and so you you keep watch on this, uh, constantly. So, um, and then there's a little bit of a feel. So so when you're first starting out, you know, it's things are a little bit clunky, and then you sort of see that things are sort of, like, moving on a regular pace Right. But not too fast. So we we had one site that, you know, the very first week, they had five patients come in. Mhmm. Uh, these are acutely psychotic patients. So, mostly, I don't care where you are in the world. You're not gonna have five acutely psychotic patients come to you in the same day, certainly, much less the same week. So just like, what's going on here? So It
Brandon Li 36:30 it it sounds like the like, a a key to all of this is is looking at the stream of data, looking at deviations, um, and trying to pick out any funny business.
Steve Brannan 36:39 Yes. I'd say that's a good part of it. Yes. much less the same week. So just like, what's going on here? So It
Brandon Li 36:30 it it sounds like the like, a a key to all of this is is looking at the stream of data, looking at deviations, um, and trying to pick out any funny business.
Steve Brannan 36:39 Yes. I'd say that's a good part of it. Yes.
Brandon Li 36:43 Maybe that's the title of the book, the the inevitable book. Pick looking for funny business.
Steve Brannan 36:50 Okay.
Brandon Li 36:51 Hey. Uh, I wanna stay on this this subject of soft endpoints. Um, we've had we've had, uh, Ray Sanchez from Cereval on the show as well. And, um, we kind of, um, asked him, uh, what would he like to to kind of ask you? And, uh, one of the one of the questions that came up with, uh, that that kind of came up in the prep was, um, talking about the trajectory of precision psychiatry and how it might evolve in the the kind of landscape of, uh, psychiatric trials, which have historically have these, uh, subjective endpoints?
Steve Brannan 37:21 Well, we we certainly need it. I mean, you know, and it's not just in terms of the outcome. It's just also diagnosis. So somebody walks in, and a a good psychiatrist should be able to distinguish certain things. But, like, uh, there's things commonly, like, somebody who's bipolar but psychotic or schizophrenia and psychotic. It's really hard to tell the difference between them, uh, you know, in a couple of days or even a week. So, um, we don't have something like if you're in diabetes trials. You know? You had a hemoglobin a one c. So that is hard to think.
Brandon Li 37:56 Mhmm.
Steve Brannan 37:56 And so you have a much more precision in terms of knowing stuff. So it would be great if we could start and people have been talking about this and probably promising too much too quickly, frankly. Um, but, uh, I think, you know, this is also part of the the future as well as the present, but these so called digital biomarkers. So, um, in schizophrenia, we've known for over a hundred years their speech is different. Um, but now we can record just like you're recording me now and and play the stuff back and look at all sorts of things that that you we normally don't hear in terms of tone and pauses and all this kind of stuff, and you can track it with the AI and similar sorts of things, and and you see a pretty big difference. So so these are things I think are gonna evolve in the next five to ten years, and I think they're they're sorely needed because even things I talk about schizophrenia or depression, uh, they're not one thing. They're they're probably three or four, maybe more kinds of things that we all budge together. And so if we can disentangle that, I think our treatments will get better and these trials will get better. So we'll we'll know that we've got, you know, the right, uh, more more assurance that we have the right subject in for that trial.
Brandon Li 39:13 What what do you think it's gonna take to to bring these digital biomarkers through to research and and clinical practice? t better and these trials will get better. So we'll we'll know that we've got, you know, the right, uh, more more assurance that we have the right subject in for that trial. What what do you think it's gonna take to to bring these digital biomarkers through to research and and clinical practice?
Steve Brannan 39:22 Uh, yeah. Please. Well, it may come to clinical practice before it does research. Uh, one one of the big needs we have is for both sponsors and the regulators to to move quicker than molasses.
Brandon Li 39:34 Mhmm.
Steve Brannan 39:35 So, um, and it's not just the regulatory folks because the big companies in particular can be very slow to adopt something. So in one of our trials, we put something in. We we didn't put it in the, uh, pivotal trials, but it was in the safety trial. So that's something called ecological momentary assessment. So this is a very new thing in the last five, ten years. And maybe it's longer, but at least in terms of, you know, being up in front of people, it's basically you've got these little phones, and so they can send you out a text or a message or whatever, uh, you know, once, twice, three times a day, maybe more, and say, oh, you know, where are you? Who are you with? Uh, what are you doing? Uh, and you get this sort of information, uh, but also are are the voices bothering you? And and so we stuck this in some of our safety study, and it's amazing what this looks like. And you have a lot more power because you're you're not just asking somebody once a week at at that's about as quick as you'll you'll do stuff with people. Uh, and, you know, over the last week, you know, how are how bad were the voices? You know? It it's it's hard for, you know, some of us to remember exactly what we ate for breakfast three days ago. You know? Other stuff. So I think there's gonna be a lot more power in this, and I'm hoping that, uh, there'll be enough flexibility without being crazy about stuff. But, you know, let let's figure this out. Let's use this because we we really sorely need it, and I think it could really help a lot of these trials. There there are also gonna jump in on this, what what are called duplicate patients in these trials. Yeah. And, uh, this is also in more tech savvy places. So, you know, there's both pluses and minuses to tech. And these are people who are faking, you know, schizophrenia or psychosis or faking depression or what whatever. It it's really fraud. And, um, I I don't have a warm, fuzzy place in my heart for these people. For the most part, they're they're just committing fraud. But, nonetheless, um, you know, we have to do all these things to, uh, try and keep that to a minimum. And I think one of our successes is we we really did keep that to a minimum in our trials. Unfortunately, a lot of people are not doing this. So as I've said, it's sort of like, you know, beware of dog sign for your burglars in your backyard. You know? It's like, oh, there's another house I can go to that doesn't have a dog that I can rob. r successes is we we really did keep that to a minimum in our trials. Unfortunately, a lot of people are not doing this. So as I've said, it's sort of like, you know, beware of dog sign for your burglars in your backyard. You know? It's like, oh, there's another house I can go to that doesn't have a dog that I can rob.
Brandon Li 42:04 Yeah. So Well well, certainly, uh, we've been seeing a a trend towards, uh, more automated systems for checking for potentially fraudulent entries, um, in research studies. Yeah.
Steve Brannan 42:17 In that first wave of studies at at Takeda, as I told you about, in the very first two studies,
Brandon Li 42:21 we Oh.
Steve Brannan 42:21 There was 23 people in both studies at the same time. Wow. Yeah. So, yeah, it it is unfortunately a necessary evil, sort of like all the TSA stuff you have to do at the airport. I I didn't have to do my news, but, you know.
Brandon Li 42:37 Well, you know, back to this theme of, uh, monitoring the data and looking for funny business. Um, this is just another form of funny business. Um, hey, you know, one of the things that comes up as we explore vocal biomarkers, it's a thing that we've explored on our end, whereby, you know, when patients sign up on our platform, we might have a conversation with them and then, uh, and then kind of use that to kind of inform some of these vocal biomarkers. One of the things that has come up is, uh, is there a downstream, like, uh, impact on the regulatory submission, um, that is required if that's a kind of criteria for entry, um, into the study?
Steve Brannan 43:17 Um, that's a tricky question. And there's an implication for it. Um, but they are okay with you enriching your trials. So and there's a whole guidance on on this. And from my understanding of that and my understanding of vocal or facial biomarkers, uh, that would be fine. Now you might get a line in your, uh, label that says, you know, that this drug worked in people who had a you know, met these criteria and and met the vocal facial biomarker, blah blah blah blah. So you might have a little bit of a limitation there, but, uh, that wouldn't be all bad either because then whoever you know? Then you could start getting into clinical practice like, oh, maybe you wanna do your vocal biomarker, uh, which is pretty easy. Uh, should be able to be done, I think, in the future fairly cheaply as well. So
Brandon Li 44:11 I guess somebody needs to start with a validated diagnostic.
Steve Brannan 44:14 Yeah. You it's the validation, uh, piece, which can take a long time. Uh, but I don't think you need to have that all fully validated, uh, for the enrichment. Um, so, for instance, we don't take on, you know, the pants between 80 and one twenty. You know? So we that that's in the label of what we did, but but the, um, FDA label doesn't restrict it to people who are not between 80 and one twenty. So on't think you need to have that all fully validated, uh, for the enrichment. Um, so, for instance, we don't take on, you know, the pants between 80 and one twenty. You know? So we that that's in the label of what we did, but but the, um, FDA label doesn't restrict it to people who are not between 80 and one twenty. So
Brandon Li 44:41 Certainly. One of the things that has been a theme on this show and and some of the and some of the guests we've spoken to is this idea of us being in a in a neuroscience renaissance, if you will. Yeah. Uh, I'm curious, uh, what do you attribute that to?
Steve Brannan 45:00 Uh, these things always are sick. You know? They they go up and they go down, uh, and and some of it doesn't make any sense. But but, uh, you know, one of the things people ask is like, well, why didn't Lilly do what you guys did with, you know, uh, thirty years ago? And the answer was they couldn't have. They they didn't have the techniques. They didn't have the things that could be done today. They tried sorts of different things, but but but the field had not advanced, and the field is just advancing so quickly on so many fronts. We have a lot better genetics. We have a lot better imaging. Just all sorts of things. Just even techniques, clinical methodology, we we have caught up to some of these, you know, duplicate patients. Uh, nonadherence is another big issue, especially like in schizophrenia. Sure.
Brandon Li 45:49 Yeah.
Steve Brannan 45:51 Um, actually, sorry. This is a bit of a non sequitur, but we've been talking about face and and voice. So, uh, one of the things that typical schizophrenia patients do not have is good social cognition. And so we we were playing back on one of our subjects, uh, this patient, and he was telling a joke on the tape. And according to the person who listened to it, it was a pretty good joke. And then he stopped and thought, wait a second. How many acutely psychotic patients with schizophrenia can tell a joke? Oh. The answer is zero. Oh. So so, you know, there's things you can pick up, uh, but I think in the future, we'll we'll be a lot more subtle and and more precise.
Brandon Li 46:37 Yeah. You know, another question from Ray. Um, are you are you optimistic or pessimistic as far as AI, um, and defining clinical and clinical development, um, and its applications? ere's things you can pick up, uh, but I think in the future, we'll we'll be a lot more subtle and and more precise. Yeah. You know, another question from Ray. Um, are you are you optimistic or pessimistic as far as AI, um, and defining clinical and clinical development, um, and its applications?
Steve Brannan 46:52 Um, in between. Neutral. Neutral. Well, uh, you know, people used to ask me, you know, like, in high school, like, what's your favorite color? I don't have a favorite color, but, uh, you know, my shirt here is black. So I I used to tell them black because I learned if I said black, they'd stop and leave me alone. Right. But it wasn't my favorite color. Um, AI is going to be, even this year, useful for certain things. Uh, part of the problem is people come in with all this hype, and it's like, oh, this is the best thing since sliced bread. By next year, everything will be run by AI, and it's like, no. No. No. And when when they say they can figure out new targets, no, they can't because no one knows what the new targets are. So just don't go there. But, um, there are things that it can do very quickly. It can it it can monitor, you know, the, um, uh, interviews that we do, uh, for quality and for all sorts of things just very quickly. It never gets tired. It doesn't get grumpy. Consistent? Yeah. Uh, well, in the standard, uh, acute psychosis in schizophrenia trials, you there's a bunch of them out there, uh, and you can probably get AI to do this. Now don't make it your final draft. Don't don't be stupid. But, you know, let it do that. It could do a kinda a clinical, uh, the CSR, the clinical scientific report of of the study. Um, it could take a protocol, and then we we have our CRFs, you know, so our our report forms that we have to do. And and it can do all these things. Again, first, maybe second round
Brandon Li 48:32 Draft.
Steve Brannan 48:32 To find the yeah. Draft. And and this saves time. So it'll it'll it'll be good. Uh, so there are those sorts of things just as long as you don't. Now some of the more subtle things, you know, we're talking about, like, how how do you interact with your side with that soft touch on the
Brandon Li 48:48 Yeah.
Steve Brannan 48:49 Can't get there.
Brandon Li 48:50 Yeah. Do that.
Steve Brannan 48:51 Uh, our you know, this feel about, something's not quite right with this patient. Probably can't do that. Uh, so but but, um, it it will you know, if you pair it with some of these digital biomarkers, it you you know, if we you or I were to look at all the stuff and and do the measurements, we could do it, but it would just take us a couple of days, and it's gonna take two minutes. So you you can get back to the sites in a very timely manner, uh, on the digital volume market, for instance. these digital biomarkers, it you you know, if we you or I were to look at all the stuff and and do the measurements, we could do it, but it would just take us a couple of days, and it's gonna take two minutes. So you you can get back to the sites in a very timely manner, uh, on the digital volume market, for instance.
Brandon Li 49:23 Yeah. Certainly. I think that, uh, analyzing call recordings, these kinds of things, incredible opportunity drafting, uh, documentation, uh, based on, uh, whatever's in the in the information. Incredible. Uh, you did mention pessimism around, um, target design, uh, and you you kicked off this conversation with, uh, with excitement around targets. So I'd love to just hear you opine on, um, what you're seeing and what you're excited about.
Steve Brannan 49:47 Yeah. So the, um, neuroplasticens is the really interesting brings some difficulties as well, and a lot of this is through the so called psychedelics. So, again, talk about something that was overhyped. I'm old enough to remember some of the psychedelic stuff and walking through Harvard Square and looking at people who'd overdone it. Kept me from trying any of that stuff. Um, but, uh, there is a neuroplasticogen is something you you you give it once, maybe twice, and then all this other stuff happens, you know, uh, whether it's guided by therapy or maybe not. Uh, but it also poses some stuff. So so we talk about dose ranging studies. You know? How do you do a dose ranging study with, you know, some of these things that you you give and then it has an effect for, you know, four or five months? It's gonna be pretty hard to do that dose finding study. So there's there's all sorts of pluses and minuses that go with this, but but, uh, we're just scratching the surface on this. Um, does it do you have to have a hallucinogenic experience or not? I'm not sure you do. So, um, and they're talking about microdoses again. So you we're always talking in the dosing about enough to have an impact, but not too much to overdo it, uh, and maybe throw something else in your body off balance, so to speak. Um, so I think that that's that's really interesting. And then I I already told you about this ecological momentary assessment, which is part of this whole new rate. And there's all sorts of digital biomarkers. Uh, there's stuff you can do in Parkinson's disease for just movement. Uh, so so we're on the brink of a lot of things, I think, that could be very powerful in terms of giving us better insight or better more granular data on on what's going on. So and then just the field itself is also progressing at a rapid pace in terms of some of the imaging stuff, genetics. Uh, we're we're a lot you know, brain's very complicated, and and genetics is very complicated. So you're you're not gonna have this huge jump, but you're you're gonna have better and better granularity built built out over the next decade or so, in my opinion. apid pace in terms of some of the imaging stuff, genetics. Uh, we're we're a lot you know, brain's very complicated, and and genetics is very complicated. So you're you're not gonna have this huge jump, but you're you're gonna have better and better granularity built built out over the next decade or so, in my opinion.
Brandon Li 52:04 There there's this implied thesis, um, that, uh, I'd like the name here for a moment, um, which is that precision, I guess, like precision medicine in psychiatry, uh, doesn't necessarily need to be revolved around, uh, biomarkers in the traditional sense, right? Genetic biomarkers in the traditional sense as we think about it. I think there are interesting digital precision, um, components in psychiatry that to your point, we can use video, can use audio, can use, um, I guess video recordings of movement, um, uh, to kind of, uh, to kind of inform some of the decision making.
Steve Brannan 52:38 You yeah. No. You can just use movement devices. Uh, it doesn't have to be video. So, um, you know, how people move, how they you know, they they did some of this on the schizophrenia trial, long term schizophrenia trial, and so people wouldn't be like, what what where are you? Well, I'm home alone. And then the actigraphy would basically not show a lot of movement that if they said, oh, yeah. I'm out and doing the, then the actigraphy showed. You know? So this gets back to your site, you know, watching for things and making sure things aren't there's no funny business. But but yeah. No. You can tell a lot even just from actigraphy. Yeah. And sleep is a whole another thing that that they're working on. I think they they're gonna have some devices that'll give you some really good information without having to go into a sleep lab, which is expensive and problematic for a lot of people.
Brandon Li 53:27 Yeah. Yeah. Um, and talk about patient burden. Right?
Steve Brannan 53:31 And decrease patient burden, which, lord knows, is is the patients or the participants can tell you in these trials can be a real pain in the butt.
Brandon Li 53:40 Absolutely. Uh, maybe kind of the, the last kind of topic I'd like to, to linger on here very quickly. Um, you mentioned neuroplasticity as a, uh, an interesting topic of, um, kind of exploration here. Um, it it seems like the the kind of bulk of the discussion now is whether they will resonate in a regulatory, uh, uh, kind of landscape. I'd love to hear how you how you're thinking about that today. n here very quickly. Um, you mentioned neuroplasticity as a, uh, an interesting topic of, um, kind of exploration here. Um, it it seems like the the kind of bulk of the discussion now is whether they will resonate in a regulatory, uh, uh, kind of landscape. I'd love to hear how you how you're thinking about that today.
Steve Brannan 54:15 Well, uh, you know, some of the stuff I mentioned may makes it difficult for the regulators. So it's like, what is the dose range? You know? Not only do we not know for this particular compound, we're not even sure how to do it. Mhmm. So so that just makes it hard to write the label and stuff like that. Um, so so they do have some legitimate concerns about some of this. And then some of the people in this field, like, um, I'm probably gonna get this wrong, but but, oh, we don't need to do talk studies because, you know, enough people took this in the sixties and seventies that we know it's safe. You know? No. Safety's still important. Or, oh, yeah. They they got high, but we we didn't put that down, you know, as a potential, uh, side effect. It's like, that was stupid. So, you know, learn a little bit about what's going on. And so, uh, you know, some of the Lycos, uh, which was the first one Sure. They just didn't really know exactly how how you chat with the FDA. I guess that's another thing you learn with experience. Uh, there's ways to approach it and ways not to approach it.
Brandon Li 55:30 Are you are you keen to get in the game and apply your your kind of history of expertise to to this field?
Steve Brannan 55:40 Not not exactly. Uh, let let me phrase it slightly differently. So there appear to be a number of companies, including in this field, that would like me to assist them, you know, in some of the stuff. And, again, I'm happy to assist people on things that I think, you know, like, you know, we we were talking about earlier. If there's things that can make these better studies and get stat to get things or or determine whether it's good or not for patients and do that more quickly, more efficiently, I'm happy to do that. So and right now, because of all the things that are going on and, you know, there's stuff like, uh, PTSD or post traumatic stress disorder that, really, we don't have anything that effective for. And if this stuff can be effective, at least for a subset of them, yeah, I'd love to see that happen. So
Brandon Li 56:29 Well, you you you heard it here first, folks. Um, for the for the psychedelic, um, companies that follow along, Steve is, uh, Steve is open for consultations. ave anything that effective for. And if this stuff can be effective, at least for a subset of them, yeah, I'd love to see that happen. So Well, you you you heard it here first, folks. Um, for the for the psychedelic, um, companies that follow along, Steve is, uh, Steve is open for consultations.
Steve Brannan 56:37 Oh, no, please don't. Ray Sanchez. Ray is also open for consultations. Um, Steve, uh, I've so enjoyed this time. Uh, my last question um Peep people, uh, you know, this is a couple years ago, but I remember there's a big investor meeting in Boston, and they were talking about all these things and and, you know, their what they look at, blah blah blah. And I said, well, do you ever look at the clinical operations team? And they're like, no. Why would we do that? I'm like, because the execution of the trial is, like, one of the the major differences of whether you succeed or not, at least in CNS. And they they sorta nod their head, looks at me, and then went on to their conversation. Yeah. A little bit of the unsung heroes. A little bit of the unsung heroes. Yeah. Yeah. Exactly. And I think the fact that it's not asked enough is partly because it's not emphasized enough. And some of the things that, uh, you know, you and I talked about in terms of the speed, optimal speed, and blah blah blah. You know? There's things out there we know, but people just blow them off or think that that, you know, they can ignore that side of the the business. But clinical trial methodology is the key to really having consistently good trials going and executing.
Brandon Li 58:07 Well, I'm so glad you you ended it there because, um, it is a foreshadow for the next kind of season that we are pursuing. So, um, stay tuned as we, um, we kind of a deep dive on on ClinOps, uh, excellence.
Steve Brannan 58:19 Alright. Alright. Thanks, Brandon.
Brandon Li 58:20 Well, Steven, thank you so much for your time. I'm gonna I'm gonna hit stop here, but I'm gonna ask you to stay on the line, uh, because it does need to finish uploading the recording.